LYEL vs ZION · rev $6.0K vs P/E 11, rev $354.0M
Lyell Immunopharma Inc (LYEL) versus Zions Bancorporation (ZION) — a side-by-side from cached financials, not a winner call.
Lyell Immunopharma Inc (LYEL) is a biotechnology company listed on US.
Zions Bancorporation (ZION) is a banks - regional company listed on US.
Latest reported LYEL revenue for 2026-06-30 was $6.0K. Net income was -$68.9M. LYEL currently screens at market cap $143.5M.
Latest reported ZION revenue for 2026-06-30 was $354.0M. Net income was $686.0M. ZION currently screens at market cap $8.19B and trailing P/E 10.8.
LYEL currently screens at market cap $143.5M. ZION currently screens at market cap $8.19B and trailing P/E 10.8.
Not investment advice. Open the LYEL and ZION stock pages for the full models.
Not investment advice.